Biomimetic Therapeutics, Inc. (BMTI) Company Profile - CorporateInformation.com

Company Search:

Advanced Search

Wright Investors Service Perspectives


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Biomimetic Therapeutics, Inc. Company Snapshot

Business Description:

Biomimetic Therapeutics, Inc. operates in the Surgical and medical instruments sector. BioMimetic Therapeutics, Inc. is a biotechnology company. The Company develops and commercializes products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, sports medicine and spine applications. Its product and product candidates uses recombinant human platelet derived growth factor (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body, in combination with tissue specific matrices when appropriate. The Company's first periodontal product is GEM 21S Growth-factor Enhanced Matrix (GEM 21S) and its first orthopedic product is Augment Bone Graft (Augment). Both GEM 21S and Augment are synthetic, off-the-shelf bone growth factor products for the treatment of bone defects and injuries. As of December 31, 2010, the Company's product candidates included Augment Bone Graft, Augment Injectable Bone Graft, Augment Rotator Cuff Graft, Augment OCD, Product Name TBD and Augment Bone Graft. In our complete report available for purchase the company is compared to: Daxor Corporation, Tearlab Corporation and Hypertension Diagnostics, Inc..

Biomimetic Therapeutics, Inc.

Stock Performance Chart for Biomimetic Therapeutics, Inc.

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 2.06
(Figures in U.S. Dollars)

1 Week	1.5%		13 Weeks	3.0%

4 Weeks	-35.8%		52 Weeks	-85.2%

Biomimetic Therapeutics, Inc. Key Data:

	Ticker:	BMTI	Country:	UNITED STATES

	Exchanges:	NAS	Major Industry:	Drugs, Cosmetics & Health Care

			Sub Industry:	Ethical Drug Manufacturers

	2010 Sales	1,473,525 (Year Ending Jan 2011).	Employees:	95

	Currency:	U.S. Dollars	Market Cap:	57,796,652

	Fiscal Yr Ends:	December	Shares Outstanding:	28,056,627

	Share Type:	Common	Closely Held Shares:	8,032,253

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.